Mode
Text Size
Log in / Sign up
Phase 3 Completed N=838 Randomized Treatment

Intravenous Thyroxine for Heart-Eligible Organ Donors

Brain Death · Heart Failure
Source: ClinicalTrials.gov NCT04415658 ↗
Enrolled (actual)
838
Serious AEs
0.6%
Results posted
Jan 2024
Primary outcomePrimary: Heart Transplanted — 230; 223 Participants — p=0.57
◆ Published Evidence
Established
44citations · ~15 / year
Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors.
The New England journal of medicine · 2023 · Open access · Likely link

Summary

This randomized controlled trial will evaluate whether intravenous thyroxine infusion given to brain-dead organ donors who are eligible to donate hearts for 12 hours will result in more hearts transplanted than saline placebo

Linked Publications (2)

  • Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors.
    The New England journal of medicine · 2023 · 44 citations · Open access · Likely link
  • A multicenter randomized placebo-controlled trial of intravenous thyroxine for heart-eligible brain-dead organ donors.
    Trials · 2021 · 12 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Heart Transplanted
230; 223 0.57
PRIMARY
Graft Function
224; 213 <0.001 sig
SECONDARY
Time Till Off Vasopressors
22; 25
SECONDARY
Weaned Off Vasopressors
143; 152
SECONDARY
Time to Order Echo
12; 13
SECONDARY
Ejection Fraction
59; 58
SECONDARY
Lungs Transplanted
163; 149

Eligibility Criteria

Inclusion Criteria

  • Declared dead by neurologic criteria (brain dead)
  • Authorization for organ donation and research
  • On one or more vasopressors and/or inotropes

Exclusion Criteria

  • Brain death declared more than 24 hours prior
  • Only vasopressor is vasopressin
  • Weight < 45 kg (100 lbs)
  • Known coronary artery disease or history of myocardial infarction
  • Known valvular heart disease
  • Prior sternotomy or cardiac surgery
  • Donor at VA hospital
  • Received intravenous or oral thyroxine within past month
  • Known HIV+ status
  • Other reason donor is unable to receive study drug (determined by on-site personnel)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04415658) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search